Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.66 |
| ▸ | GAA | P10253 | 2/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | ERN1 | O75460 | 1/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6359372 | 0.91 | SMN1; SMN2 (0.72) | ALDH1A1GAAHSD17B10L3MBTL1KMT2A | |
| SCHEMBL12319476 | 0.88 | ALDH1A1 (0.66) | ALDH1A1GAAHSD17B10L3MBTL1KMT2A | |
| SCHEMBL13753335 | 0.88 | ALDH1A1 (0.69) | ALDH1A1GAAHSD17B10KMT2APOLB | |
| SCHEMBL12319414 | 0.84 | ALDH1A1 (0.61) | ALDH1A1GAAHSD17B10L3MBTL1KMT2A | |
| SCHEMBL19072052 | 0.84 | ALDH1A1 (0.61) | ALDH1A1GAAHSD17B10KMT2AMEN1 | |
| SCHEMBL25492516 | 0.84 | L3MBTL1 (0.62) | ALDH1A1GAAHSD17B10L3MBTL1KMT2A | |
| SCHEMBL13763531 | 0.84 | L3MBTL1 (0.80) | ALDH1A1GAAHSD17B10L3MBTL1KMT2A | |
| SCHEMBL7705708 | 0.83 | ALDH1A1 (0.76) | ALDH1A1GAAHSD17B10L3MBTL1KMT2A | |
| SCHEMBL14482756 | 0.81 | ALDH1A1 (0.64) | ALDH1A1GAAHSD17B10KMT2AMEN1 | |
| SCHEMBL29646375 | 0.81 | ALDH1A1 (0.64) | ALDH1A1GAAHSD17B10KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168654-B2 | Quinuclidine derivatives binding to mucarinic M3 receptors | NOVARTIS AG (CH) | 2012-05-01 | — | — | US | disclosed |
| US-8168654-B2 | Quinuclidine derivatives binding to mucarinic M3 receptors | NOVARTIS AG (CH) | 2012-05-01 | — | — | US | disclosed |
| US-20100041887-A1 | QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS | COLLINGWOOD STEPHEN PAUL | 2010-02-18 | — | — | US | disclosed |
| US-20100041887-A1 | QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS | COLLINGWOOD STEPHEN PAUL | 2010-02-18 | — | — | US | disclosed |
| US-20070060563-A1 | Quinuclidine derivatives binding to mucarinic m3 receptors | NOVARTIS AG (CH) | 2007-03-15 | — | — | US | disclosed |
| US-20070060563-A1 | Quinuclidine derivatives binding to mucarinic m3 receptors | NOVARTIS AG (CH) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060563-A1 | Quinuclidine derivatives binding to mucarinic m3 receptors | CHRM3, CHRM2, CHRM1 | ALDH1A1 1477/4885GAA 1880/4885HSD17B10 3721/4885 |
| US-20100041887-A1 | QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS | CHRM3, CHRM2, CHRM1 | ALDH1A1 1477/4885GAA 1880/4885HSD17B10 3721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.